Somatostatin receptor 3

SSTR3
Identifiers
AliasesSSTR3, SS-3-R, SS3-R, SS3R, SSR-28, Somatostatin receptor 3
External IDsOMIM: 182453; MGI: 98329; HomoloGene: 20285; GeneCards: SSTR3; OMA:SSTR3 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

6753

20607

Ensembl

ENSG00000278195

ENSMUSG00000044933

UniProt

P32745

P30935

RefSeq (mRNA)

NM_001051
NM_001278687

NM_009218
NM_001356961

RefSeq (protein)

NP_001042
NP_001265616

NP_033244
NP_001343890

Location (UCSC)Chr 22: 37.2 – 37.21 MbChr 15: 78.42 – 78.43 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Somatostatin receptor type 3 is a protein that in humans is encoded by the SSTR3 gene.[5][6]

Function

Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. The biological effects of somatostatin are probably mediated by a family of G protein-coupled receptors that are expressed in a tissue-specific manner. SSTR3 is a member of the superfamily of receptors having seven transmembrane segments and is expressed in highest levels in brain and pancreatic islets. SSTR3 is functionally coupled to adenylyl cyclase.[6]

Ligands

Agonists
Antagonists

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000278195Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000044933Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Yamada Y, Stoffel M, Espinosa R, Xiang KS, Seino M, Seino S, Le Beau MM, Bell GI (February 1993). "Human somatostatin receptor genes: localization to human chromosomes 14, 17, and 22 and identification of simple tandem repeat polymorphisms". Genomics. 15 (2): 449–52. doi:10.1006/geno.1993.1088. PMID 8449518.
  6. ^ a b "Entrez Gene: SSTR3 somatostatin receptor 3".
  7. ^ Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, Albini A. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology. 2003 Apr;144(4):1574-84. doi:10.1210/en.2002-220949 PMID 12639942
  8. ^ Poitout L, Roubert P, Contour-Galcéra MO, Moinet C, Lannoy J, Pommier J, Plas P, Bigg D, Thurieau C. Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. J Med Chem. 2001 Aug 30;44(18):2990-3000. doi:10.1021/jm0108449 PMID 11520208
  9. ^ Shah SK, He S, Guo L, Truong Q, Qi H, Du W, Lai Z, Liu J, Jian T, Hong Q, Dobbelaar P, Ye Z, Sherer E, Feng Z, Yu Y, Wong F, Samuel K, Madiera M, Karanam BV, Reddy VB, Mitelman S, Tong SX, Chicchi GG, Tsao KL, Trusca D, Feng Y, Wu M, Shao Q, Trujillo ME, Eiermann GJ, Li C, Pachanski M, Fernandez G, Nelson D, Bunting P, Morissette P, Volksdorf S, Kerr J, Zhang BB, Howard AD, Zhou YP, Pasternak A, Nargund RP, Hagmann WK. Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes. ACS Med Chem Lett. 2015 Mar 18;6(5):513-7. doi:10.1021/ml500514w PMID 26005524
  10. ^ He S, Ye Z, Truong Q, Shah S, Du W, Guo L, Dobbelaar PH, Lai Z, Liu J, Jian T, Qi H, Bakshi RK, Hong Q, Dellureficio J, Pasternak A, Feng Z, deJesus R, Yang L, Reibarkh M, Bradley SA, Holmes MA, Ball RG, Ruck RT, Huffman MA, Wong F, Samuel K, Reddy VB, Mitelman S, Tong SX, Chicchi GG, Tsao KL, Trusca D, Wu M, Shao Q, Trujillo ME, Eiermann GJ, Li C, Zhang BB, Howard AD, Zhou YP, Nargund RP, Hagmann WK. The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes. ACS Med Chem Lett. 2012 May 7;3(6):484-9. doi:10.1021/ml300063m PMID 24900499

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.